Vol 6, No 2 (2009)
- Year: 2009
- Articles: 12
- URL: https://journals.eco-vector.com/2075-082X/issue/view/1627
Articles
Efficacy of metoprolol in treatment and preventive of cardiovascular diseases
Systemic Hypertension. 2009;6(2):4-7
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Amlodipin in the treatment of arterial hypertension
Systemic Hypertension. 2009;6(2):7-10
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Perindopril in treatment of patients with arterial hypertension and high cardiovascular risk
Systemic Hypertension. 2009;6(2):10-15
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Obstructive sleep apnea syndrome
Systemic Hypertension. 2009;6(2):15-21
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
The intensive control of blood pressure: possibilities of the combined therapy.
Systemic Hypertension. 2009;6(2):22-27
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Arterial hypertension and sleep apnea in pediatrics: results of pilot trial
Systemic Hypertension. 2009;6(2):28-31
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Combined low-dose therapy of arterial hypertension
Systemic Hypertension. 2009;6(2):31-34
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Sartans in cardiological practice: new possibilities in therapy of cardiovascular diseases
Systemic Hypertension. 2009;6(2):34-38
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Perspectives of using angiotensin receptor antagonists
Systemic Hypertension. 2009;6(2):38-43
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
HYVET: landmark trial voted 2008 Trialof the Year by the ImpACT/Society for Clinical Trials and the American Heart Association
Systemic Hypertension. 2009;6(2):44-45
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Vozmozhnosti telmisartana v ANGIO- i KArdioprotektsii i uluchshenii pokazateley uglevodnogo obmena pri narushenii tolerantnosti k glyukoze
Systemic Hypertension. 2009;6(2):47-50
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
The level of uric acid and its role at early stages of essential hypertension
Abstract
Aim: correlation of uric acid (UA) level on serum blood and urine with indicators of not specific inflammation and clinical
characteristic in essential hypertension (EH) patients. Methods: 67 patients with EH (48 men) 30-65 years age (442) with
stage 1 EH (n=37) and 2 (n=30) with moderate or high cardiovascular (CV) risk. The control group - 14 healthy peoples: (6
men) 45,52,1 years age with normal blood pressure (BP). The normal level of С-reactive protein (CRP) is less 3 mg/l. The
normal level of UA in blood is 202,3-416,5 mkmol/l, and in urine is 1,48-4,43 mmol/24 hour. The estimates of creatinine
clearance by the Cockroft-Gault formula. Results: the patients with EH have bigger level CRP, UA in blood and urine than
healthy peoples with normal BP. Higher levels UA in blood and urine have patients even with early stages EH and moderate
CV risk. The bigger level of UA in blood has EH patients with obesity and dyslipidaemia. The level of UA in blood and urine is
higher at EH patients with hyperfiltration vs patients with normal creatinine clearance. Conclusion: the patients with early
stage of EH have higher level of UA in blood and urine than healthy peoples with normal BP. The level of UA in blood and
urine is correlated with dyslipidaemia. Key words: essential hypertension, uric acid, non specific inflammation
Systemic Hypertension. 2009;6(2):51-56
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)